News
MHRA approves Ogluo to treat severe hypoglycaemia in patients with diabetes mellitus.- Xeris Pharma
Xeris Pharmaceuticals, Inc.a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced that the United Kingdom’s Medicines and Healthcare Regulatory Agency (MHRA) has approved Ogluo (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
Condition: Diabetes/Severe Hypoglycemia
Type: drug